Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.30 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20739117 | 1.00 | TUBB1 (0.43) | TUBB1CMA1ACEREN | |
| SCHEMBL22346164 | 1.00 | TUBB1 (0.43) | TUBB1CMA1ACEREN | |
| SCHEMBL22346161 | 1.00 | TUBB1 (0.43) | TUBB1CMA1ACEREN | |
| SCHEMBL22069906 | 0.87 | CMA1 (0.41) | TUBB1CMA1 | |
| SCHEMBL22316484 | 0.87 | TUBB1 (0.40) | TUBB1 | |
| SCHEMBL22111332 | 0.87 | TUBB1 (0.40) | TUBB1 | |
| SCHEMBL22309342 | 0.86 | TUBB1 (0.36) | TUBB1 | |
| SCHEMBL20732462 | 0.86 | TUBB1 (0.36) | TUBB1 | |
| SCHEMBL13682227 | 0.85 | TUBB1 (0.58) | TUBB1 | |
| SCHEMBL59693 | 0.85 | TUBB1 (0.58) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-30 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202948-A1 | Agent for Eliminating Pluripotent Stem Cells | POU5F1, POU2F1, POU2F2 | TUBB1 119/4885CMA1 1897/4885ACE 4382/4885 |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | TUBB1 436/4885CMA1 981/4885ACE 3373/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | TUBB1 436/4885CMA1 981/4885ACE 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.